 |
449 Diseases |  |
58 Trials |
|
58 Trials |  |
3605 News |  |
| «12...1213141516171819202122...2425» |
- | Leukine (sargramostim) / Partner Therap
Enrollment open: Safety Study of Sargramostim in Treating Patients With Mild Cognitive Impairment Due to Alzheimer's Disease (clinicaltrials.gov) - Feb 27, 2016
P2, N=30, Recruiting, Sponsor: Sanofi
Not yet recruiting --> Recruiting
- EGFR bi-armed autologous activated T cells / Barbara Ann Karmanos Cancer Institute
Trial suspension, Combination therapy, PD(L)-1 Biomarker, IO biomarker, Metastases: NCI-2015-01942: BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer (clinicaltrials.gov) - Feb 18, 2016
P1/2, N=43, Suspended, Sponsor: Barbara Ann Karmanos Cancer Institute
Not yet recruiting --> Recruiting Recruiting --> Suspended
- Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap, Leukine (sargramostim) / Partner Therap
Trial suspension: Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma (clinicaltrials.gov) - Feb 17, 2016
P1/2, N=40, Suspended, Sponsor: Barbara Ann Karmanos Cancer Institute
Recruiting --> Suspended Active, not recruiting --> Suspended
- Leukine (sargramostim) / Partner Therap
Enrollment change, Trial withdrawal: Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent (clinicaltrials.gov) - Feb 17, 2016
P1, N=0, Withdrawn, Sponsor: Barbara Ann Karmanos Cancer Institute
Active, not recruiting --> Suspended N=20 --> 0 | Recruiting --> Withdrawn
- Leukine (sargramostim) / Partner Therap
Trial primary completion date: Study of the Safety & Efficacy of Leukine (clinicaltrials.gov) - Feb 12, 2016
P2, N=40, Recruiting, Sponsor: University of Colorado, Denver
N=20 --> 0 | Recruiting --> Withdrawn Trial primary completion date: Jan 2016 --> Jun 2016
- Leukine (sargramostim) / Partner Therap, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
Combination therapy, Metastases: PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer (clinicaltrials.gov) - Feb 8, 2016
P1, N=51, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jan 2016 --> Jun 2016 Trial primary completion date: Jan 2016 --> Jan 2017
- Leukine (sargramostim) / Partner Therap, Reolysin (pelareorep) / Oncolytics, Andrus Reo
Trial suspension, Combination therapy: Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or Refractory Brain Tumors (clinicaltrials.gov) - Feb 5, 2016
P1, N=21, Suspended, Sponsor: Mayo Clinic
Trial primary completion date: Jan 2016 --> Jan 2017 Recruiting --> Suspended
- EGFR bi-armed autologous activated T cells / Barbara Ann Karmanos Cancer Institute
Enrollment open, Combination therapy, PD(L)-1 Biomarker, IO biomarker, Metastases: NCI-2015-01942: BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer (clinicaltrials.gov) - Feb 4, 2016
P1/2, N=43, Recruiting, Sponsor: Barbara Ann Karmanos Cancer Institute
Recruiting --> Suspended Not yet recruiting --> Recruiting
- || Leukine (sargramostim) / Partner Therap, Rituxan (rituximab) / Roche
Trial primary completion date, Combination therapy: Rituximab Plus Sargramostim (GM-CSF) In Patients With Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Feb 3, 2016
P2, N=130, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Trial primary completion date: Aug 2016 --> Aug 2017
- humanised dinutuximab (Hu14.18K322A) / Essential Pharma
Phase classification, Enrollment change: Combination Chemotherapy, Monoclonal Antibody, and Natural Killer Cells in Treating Young Patients With Recurrent or Refractory Neuroblastoma (clinicaltrials.gov) - Feb 3, 2016
P1, N=34, Active, not recruiting, Sponsor: St. Jude Children's Research Hospital
Trial primary completion date: Aug 2016 --> Aug 2017 Phase classification: P=N/A --> P1 | N=20 --> 34
- ||| Leukine (sargramostim) / Partner Therap
Trial initiation date, Trial primary completion date: Open Label Study of Sargramostim Among Patients Receiving Myelosuppressive Induction Chemotherapy for Acute Myelogenous Leukemia (clinicaltrials.gov) - Feb 3, 2016
P2, N=165, Not yet recruiting, Sponsor: Sanofi
Phase classification: P=N/A --> P1 | N=20 --> 34 Initiation date: Mar 2016 --> Jun 2016 | Trial primary completion date: Mar 2021 --> Jun 2021
- Leukine (sargramostim) / Partner Therap, Rituxan (rituximab) / Roche
Trial primary completion date: Rituximab Plus CHOP With Sargramostim in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Feb 3, 2016
P2, N=52, Active, not recruiting, Sponsor: University of Southern California
Initiation date: Mar 2016 --> Jun 2016 | Trial primary completion date: Mar 2021 --> Jun 2021 Trial primary completion date: Jan 2016 --> Jan 2017
- | Leukine (sargramostim) / Partner Therap
New P2 trial: Safety Study of Sargramostim in Treating Patients With Mild Cognitive Impairment Due to Alzheimer's Disease (clinicaltrials.gov) - Jan 29, 2016
P2, N=30, Not yet recruiting, Sponsor: Sanofi
- Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap, Leukine (sargramostim) / Partner Therap
Enrollment closed, Trial primary completion date: Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma (clinicaltrials.gov) - Jan 26, 2016
P1/2, N=40, Active, not recruiting, Sponsor: Barbara Ann Karmanos Cancer Institute
Trial primary completion date: Jan 2016 --> Jan 2017 Recruiting --> Active, not recruiting | Trial primary completion date: May 2016 --> May 2018
- Decadron (dexamethasone) / Merck (MSD), Leukine (sargramostim) / Partner Therap
Trial primary completion date: Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Jan 25, 2016
P2/3, N=60, Recruiting, Sponsor: Masonic Cancer Center, University of Minnesota
Recruiting --> Active, not recruiting | Trial primary completion date: May 2016 --> May 2018 Trial primary completion date: Dec 2015 --> Jan 2017
- | Leukine (sargramostim) / Partner Therap
Enrollment open, Trial initiation date, Trial primary completion date: GRID: GM-CSF to Decrease ICU Acquired Infections (clinicaltrials.gov) - Jan 20, 2016
P3, N=488, Recruiting, Sponsor: Hospices Civils de Lyon
Trial primary completion date: Dec 2015 --> Jan 2017 Not yet recruiting --> Recruiting | Initiation date: Mar 2015 --> Sep 2015 | Trial primary completion date: Mar 2018 --> Sep 2018
- Zeltherva (galinpepimut-S) / SELLAS Life Sciences
Trial primary completion date: WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation (clinicaltrials.gov) - Jan 17, 2016
P=N/A, N=20, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Not yet recruiting --> Recruiting | Initiation date: Mar 2015 --> Sep 2015 | Trial primary completion date: Mar 2018 --> Sep 2018 Trial primary completion date: Apr 2016 --> Apr 2017
- Rituxan (rituximab) / Roche, Zevalin (ibritumomab tiuxetan) / Servier, Aurobindo
Trial primary completion date: Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan, Melphalan, and Autologous Peripheral Stem Cell Transplant in Treating Patients With Previously Treated Multiple Myeloma (clinicaltrials.gov) - Jan 17, 2016
P1, N=42, Active, not recruiting, Sponsor: Mayo Clinic
Trial primary completion date: Apr 2016 --> Apr 2017 Trial primary completion date: Sep 2015 --> May 2016
- ProstVac (rilimogene galvacirepvec) / Bavarian Nordic
Trial primary completion date, Metastases: Vaccine Therapy With PROSTVAC/TRICOM and Flutamide Versus Flutamide Alone to Treat Prostate Cancer (clinicaltrials.gov) - Jan 17, 2016
P2, N=53, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Sep 2015 --> May 2016 Trial primary completion date: Jan 2016 --> Jan 2017
- || Libtayo (cemiplimab-rwlc) / Regeneron
Enrollment change: Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies (clinicaltrials.gov) - Jan 11, 2016
P1, N=973, Recruiting, Sponsor: Regeneron Pharmaceuticals
Trial primary completion date: Jan 2016 --> Jan 2017 N=60 --> 973
- | UV1 / Ultimovacs
Enrollment closed, Trial primary completion date: A Phase I/IIa Study of UV1 Vaccination in Patients With Non Small Cell Lung Cancer. (clinicaltrials.gov) - Jan 6, 2016
P1/2, N=21, Active, not recruiting, Sponsor: Ultimovacs AS
N=60 --> 973 Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2015 --> Mar 2016
- | Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap, Leukine (sargramostim) / Partner Therap, Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
New P2 trial: NB2013-HR German (GPOH) / Dutch (DCOG) Trial (clinicaltrials.gov) - Dec 29, 2015
P2, N=36, Recruiting, Sponsor: University of Cologne
- | Leukine (sargramostim) / Partner Therap, NeuVax (nelipepimut-S) / Dr. Reddy's
New P2 trial, IO biomarker: VADIS: Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer (clinicaltrials.gov) - Dec 22, 2015
P2, N=108, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2015 --> Mar 2016 .
- Leukine (sargramostim) / Partner Therap, Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
Combination therapy: Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma (clinicaltrials.gov) - Dec 17, 2015
P2, N=44, Recruiting, Sponsor: National Cancer Institute (NCI)
. Trial primary completion date: Apr 2017 --> Dec 2018
- Clinical: NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders (clinicaltrials.gov) - Dec 12, 2015
P2, N=41, Active, not recruiting, Sponsor: Roswell Park Cancer Institute
Trial primary completion date: Apr 2017 --> Dec 2018 Trial primary completion date: Nov 2015 --> Nov 2016
- Leukine (sargramostim) / Partner Therap, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
Surgery: Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery (clinicaltrials.gov) - Dec 9, 2015
P1, N=18, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Nov 2015 --> Nov 2016 N=14 --> 18
- Leukine (sargramostim) / Partner Therap, Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
Combination therapy: Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma (clinicaltrials.gov) - Dec 9, 2015
P2, N=44, Recruiting, Sponsor: National Cancer Institute (NCI)
N=14 --> 18 Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2018 --> Apr 2017
- EGFR bi-armed autologous activated T cells / Barbara Ann Karmanos Cancer Institute
New P1/2 trial, Combination therapy, PD(L)-1 Biomarker, IO biomarker, Metastases: NCI-2015-01942: BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer (clinicaltrials.gov) - Dec 3, 2015
P1/2, N=43, Not yet recruiting, Sponsor: Barbara Ann Karmanos Cancer Institute
- fludarabine IV / Generic mfg., busulfan / Generic mfg.
Trial primary completion date: Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease (clinicaltrials.gov) - Nov 26, 2015
P2, N=70, Active, not recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2018 --> Apr 2017 Trial primary completion date: Dec 2015 --> Dec 2016
- || Leukine (sargramostim) / Partner Therap, NeuVax (nelipepimut-S) / Dr. Reddy's, Herceptin (trastuzumab) / Roche
Trial primary completion date: Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax (clinicaltrials.gov) - Nov 22, 2015
P2, N=300, Recruiting, Sponsor: George E. Peoples
Trial primary completion date: Dec 2015 --> Dec 2016 Trial primary completion date: Dec 2015 --> Dec 2016
- Leukine (sargramostim) / Partner Therap
Trial primary completion date, Combination therapy: Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDS (clinicaltrials.gov) - Nov 21, 2015
P2, N=75, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Trial primary completion date: Dec 2015 --> Dec 2016 Trial primary completion date: Oct 2015 --> Oct 2017
- Leukine (sargramostim) / Partner Therap
Trial primary completion date: Phase I/IIa Trial of Folate Binding Protein Vaccine in Ovarian Cancer (clinicaltrials.gov) - Nov 17, 2015
P1/2, N=60, Active, not recruiting, Sponsor: COL George Peoples, MD, FACS
Trial primary completion date: Oct 2015 --> Oct 2017 Trial primary completion date: Dec 2014 --> Dec 2016
- || AE 37 / Generex, Leukine (sargramostim) / Partner Therap, GLSI-100 / Greenwich LifeSci
Trial primary completion date: BAMC-C.2007.098: Vaccine Therapy in Treating Patients With Breast Cancer (clinicaltrials.gov) - Nov 17, 2015
P2, N=600, Active, not recruiting, Sponsor: San Antonio Military Medical Center
Trial primary completion date: Dec 2014 --> Dec 2016 Trial primary completion date: Dec 2015 --> Dec 2016
- BB-MPI-03 / Benovus Bio
Trial primary completion date: BBMPI03: Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer (clinicaltrials.gov) - Nov 14, 2015
P1, N=30, Recruiting, Sponsor: Benovus Bio, Inc.
Trial primary completion date: Dec 2015 --> Dec 2016 Trial primary completion date: Oct 2015 --> Dec 2016
- ||| Leukine (sargramostim) / Partner Therap
Trial initiation date, Trial primary completion date: Open Label Study of Sargramostim Among Patients Receiving Myelosuppressive Induction Chemotherapy for Acute Myelogenous Leukemia (clinicaltrials.gov) - Nov 14, 2015
P2, N=165, Not yet recruiting, Sponsor: Sanofi
Trial primary completion date: Oct 2015 --> Dec 2016 Initiation date: Aug 2015 --> Mar 2016 | Trial primary completion date: Sep 2020 --> Mar 2021
- Targretin oral (bexarotene oral) / ReXceptor, Leukine (sargramostim) / Partner Therap
Trial primary completion date: Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia (clinicaltrials.gov) - Nov 10, 2015
P2, N=26, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Initiation date: Aug 2015 --> Mar 2016 | Trial primary completion date: Sep 2020 --> Mar 2021 Trial primary completion date: Jul 2015 --> Jul 2016
- Leukine (sargramostim) / Partner Therap
Trial primary completion date: Interferon and GM-CSF Compared With Imatinib Mesylate and Vaccine Therapy in Patients With Chronic Phase CML on a TKI (clinicaltrials.gov) - Nov 10, 2015
P2, N=56, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Trial primary completion date: Jul 2015 --> Jul 2016 Trial primary completion date: Dec 2015 --> Dec 2016
- Leukine (sargramostim) / Partner Therap
New P1 trial: iGRASP: Inhaled GM-CSF for Respiratory Virus-Associated Severe Pneumonia (clinicaltrials.gov) - Nov 10, 2015
P1, N=12, Not yet recruiting, Sponsor: Milton S. Hershey Medical Center
- Leukine (sargramostim) / Partner Therap, Neupogen (filgrastim) / Kyowa Kirin, Amgen
Enrollment open: Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis (clinicaltrials.gov) - Nov 9, 2015
P2, N=60, Recruiting, Sponsor: Virginia Commonwealth University
Trial primary completion date: Dec 2015 --> Dec 2016 Not yet recruiting --> Recruiting
- Leukine (sargramostim) / Partner Therap, Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial primary completion date: Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis (clinicaltrials.gov) - Nov 8, 2015
P2, N=60, Not yet recruiting, Sponsor: Virginia Commonwealth University
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2016 --> Dec 2025
- Leukine (sargramostim) / Partner Therap, Rituxan (rituximab) / Roche
Trial primary completion date: Rituximab + GM-CSF in Patients With Follicular B-Cell Lymphoma (clinicaltrials.gov) - Nov 5, 2015
P2, N=42, Completed, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Dec 2016 --> Dec 2025 Trial primary completion date: Sep 2013 --> Dec 2006
- Leukine (sargramostim) / Partner Therap, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
PD(L)-1 Biomarker: A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma (clinicaltrials.gov) - Nov 2, 2015
P2/3, N=400, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Sep 2013 --> Dec 2006 Trial primary completion date: Mar 2016 --> Jun 2017
- Leukine (sargramostim) / Partner Therap
Enrollment open, Trial initiation date, IO biomarker: The Immuno-Response to Primary Cryotherapy for the Treatment of Prostate Cancer (clinicaltrials.gov) - Oct 30, 2015
P1, N=20, Recruiting, Sponsor: University of Colorado, Denver
Trial primary completion date: Mar 2016 --> Jun 2017 Not yet recruiting --> Recruiting | Initiation date: Dec 2015 --> Sep 2015
- | Leukine (sargramostim) / Partner Therap, Neupogen (filgrastim) / Kyowa Kirin, Amgen
New P2 trial: Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis (clinicaltrials.gov) - Oct 30, 2015
P2, N=60, Not yet recruiting, Sponsor: Virginia Commonwealth University
- Leukine (sargramostim) / Partner Therap
Trial completion, Metastases: Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma (clinicaltrials.gov) - Oct 28, 2015
P2, N=175, Completed, Sponsor: Eastern Cooperative Oncology Group
Not yet recruiting --> Recruiting | Initiation date: Dec 2015 --> Sep 2015 Active, not recruiting --> Completed
- Zeltherva (galinpepimut-S) / SELLAS Life Sciences
Enrollment closed: WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL) (clinicaltrials.gov) - Oct 16, 2015
P2, N=29, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Leukine (sargramostim) / Partner Therap
Trial completion, Trial primary completion date: Does GM-CSF Restore Neutrophil Phagocytosis in Critical Illness? (clinicaltrials.gov) - Oct 6, 2015
P1/2, N=70, Completed, Sponsor: Newcastle-upon-Tyne Hospitals NHS Trust
Recruiting --> Active, not recruiting Recruiting --> Completed | Trial primary completion date: Apr 2015 --> Jan 2015
- Leukine (sargramostim) / Partner Therap, Yervoy (ipilimumab) / BMS
Enrollment change, Trial initiation date, Trial withdrawal: Ipilimumab and GMCSF Immunotherapy for Prostate Cancer (clinicaltrials.gov) - Oct 5, 2015
P2, N=0, Withdrawn, Sponsor: Lawrence Fong
Recruiting --> Completed | Trial primary completion date: Apr 2015 --> Jan 2015 N=54 --> 0 | Initiation date: Mar 2015 --> Jun 2015 | Not yet recruiting --> Withdrawn
- Leukine (sargramostim) / Partner Therap
Enrollment closed, Trial primary completion date: Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients (clinicaltrials.gov) - Oct 1, 2015
P1/2, N=30, Active, not recruiting, Sponsor: COL George Peoples, MD, FACS
N=54 --> 0 | Initiation date: Mar 2015 --> Jun 2015 | Not yet recruiting --> Withdrawn Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2015 --> Oct 2016
- Leukine (sargramostim) / Partner Therap
Trial primary completion date: Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer (clinicaltrials.gov) - Sep 24, 2015
P1, N=7, Active, not recruiting, Sponsor: Roswell Park Cancer Institute
Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2015 --> Oct 2016 Trial primary completion date: Aug 2015 --> Aug 2014